Biotechnology firm Pacific Edge says it's raised more than $15 million from institutional and habitual investors.
It received more than $3.5 million after completing a bookbuild on Friday, adding to the $11.4 million it had already raised.
Including a share placement it made in July, Pacific Edge, will use the $20 million collected to commercialise its Cxbladder cancer detection product in America.
